FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

_			

OMB APPROVAL

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

l	OND AFFROVAL											
	OMB Number:	3235-0287										
l	Estimated average burde	en										
l	hours per response:	0.5										

1. Name and Address of Reporting Person*  Edick Paul R					2. Issuer Name and Ticker or Trading Symbol  XERIS PHARMACEUTICALS INC [ XERS ]							(Che	Relationship of Reporting Pack all applicable)  X Director			10% O	vner		
(Last) (First) (Middle) C/O XERIS PHARMACEUTICALS, INC. 180 N. LASALLE STREET, SUITE 1810				3. Date of Earliest Transaction (Month/Day/Year) 01/31/2019								, X	X Officer (give title below) Other (specify below)  See Remarks						
(Street) CHICAGO IL 60601				_   4. _	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	. Individual or Joint/Group Filing (Check Applicable ine)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	state)	(Zip)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned  1. Title of Security (Instr. 3)  2. Transaction 3. 4. Securities Acquired (A) or 5. Amount of 6. Ownership 7. Nature of																			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					Execution Date,		Transaction Disposed Of ( Code (Instr.		es Acquired (A) or Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following		Form:	Direct Indirect Etr. 4)	. Nature of ndirect seneficial Dwnership				
								Code	v	Amount	(A) (D)	or P	rice	Reported Transaction(s) (Instr. 3 and 4)				nstr. 4)	
Common	Stock			01/3	1/201	019		Α		125,000	O <sup>(1)</sup> A \$0.00		125,0	5,000		D			
Common Stock													13,430(2)			I I I	By: Paul R. Edick 2008 Revocable Trust u/d/t lated 6/25/2018		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	L. Title of Derivative Conversion Date Execution Date, Transaction Execution Date, Transaction Conversion Date Execution Date, Transaction Execution Date, Transaction Execution Date, Transaction Date, Transaction Execution Date, Transaction Execution Date, Transaction Date, D		Transa Code (	5. Number of 6		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	derivativ Securitiv Benefici Owned Followir Reporte	ve es ially ng	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
			Code V (A) (D) Date Expiration Date Title Amount or Number of Shares			Transaction(s) (Instr. 4)													
Stock Option (right to	\$13.88	01/31/2019			A		200,000		(3)		01/31/2029	Commo		0,000	\$0.00	200,0	000	D	

## Explanation of Responses:

- 1. These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. 25% of these restricted stock units shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months.
- 2. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- 3. 25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months.

## Remarks:

Chairman, President & Chief Executive Officer

/s/ Beth Hecht, as Attorney-in-02/01/2019 **Fact** 

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.